Genetic targets in pediatric acute lymphoblastic leukemia

Advances in Experimental Medicine and Biology

Volumn 779, Issue , 2013, Pages 327-340

  Gowda, Chandrika ^a   Dovat, Sinisa ^a,b  

^a PENNSYLVANIA STATE UNIVERSITY   (United States)

^b PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

Akt; ALL; Array CGH; Ataxia telangiectasia; B cell; BCR ABL; Bloom's syndrome; CRLF2; Dasatinib; Down's syndrome; E2A HLF; E2A PBX1; ETV6 RUNX1; Fanconi anemia; FBXW7; FLT3; Gamma sectretase; HOX11; Ikaros; IKZF1; Immunophenotype; JAK mutation; Leukemia; LMO1; MLL; MYB; Neurofibromatosis; NOTCH; PAX5; Pediatric ALL; PI3K; PTEN; Ras; RUNX1; SNP; STAT; TAL1; TdT; TKI

Indexed keywords

ANTILEUKEMIC AGENT; BCR ABL PROTEIN; CD135 ANTIGEN; F BOX AND WD REPEAT DOMAIN CONTAINING 7 PROTEIN; GAMMA SECRETASE INHIBITOR; HEPATIC LEUKEMIA FACTOR; IKAROS TRANSCRIPTION FACTOR; JANUS KINASE; LESTAURTINIB; MIXED LINEAGE LEUKEMIA PROTEIN; NOTCH1 RECEPTOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN MYB; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR E2A; TRANSCRIPTION FACTOR ETV6; TRANSCRIPTION FACTOR LMO1; TRANSCRIPTION FACTOR LMO2; TRANSCRIPTION FACTOR LYL1; TRANSCRIPTION FACTOR PAX5; TRANSCRIPTION FACTOR PBX1; TRANSCRIPTION FACTOR RUNX1; TRANSCRIPTION FACTOR TAL1; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER GENETICS; CHILD; CHILDHOOD LEUKEMIA; ETVS GENE; GENE MUTATION; GENE REARRANGEMENT; GENE TARGETING; HOMEOBOX; HUMAN; LEUKEMOGENESIS; MIXED LINEAGE LEUKEMIA GENE; MOLECULARLY TARGETED THERAPY; NONHUMAN; ONSET AGE; PRIMARY TUMOR; PRIORITY JOURNAL; REVIEW; RUNX1 GENE;

EID: 84873577911     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4614-6176-0_15     Document Type: Review

References (60)

1. Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet. 2008;371(9617):1030-43. Epub 2008/03/25.
2. O'Leary M, Krailo M, Anderson JR, Reaman GH, Children's Oncology G. Progress in childhood cancer: 50 years of research collaboration, a report from the Children's oncology group. Semin Oncol. 2008;35(5):484-93. Epub 2008/10/22. 338 C. Gowda and S. Dovatt
3. Wiemels JL, Cazzaniga G, Daniotti M, Eden OB, Addison GM, Masera G, et al. Prenatal origin of acute lymphoblastic leukaemia in children. Lancet. 1999;354(9189):1499-503. Epub 1999/11/07.
4. Armstrong SA, Look AT. Molecular genetics of acute lymphoblastic leukemia. J Clin Oncol. 2005;23(26):6306-15. Epub 2005/09/13.
5. Schultz KR, Pullen DJ, Sather HN, Shuster JJ, Devidas M, Borowitz MJ, et al. Risk- And response-based classification of childhood B-precursor acute lymphoblastic leukemia: A combined analysis of prognostic markers from the pediatric oncology group (POG) and Children's cancer group (CCG). Blood. 2007;109(3):926-35. Epub 2006/09/28.
6. Borowitz MJ, Devidas M, Hunger SP, Bowman WP, Carroll AJ, Carroll WL, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: A Children's oncology group study. Blood. 2008;111(12):5477-85. Epub 2008/04/05.
7. Weinstein IB, Joe AK. Mechanisms of disease: Oncogene addiction - A rationale for molecular targeting in cancer therapy. Nat Clin Pract Oncol. 2006;3(8):448-57. Epub 2006/08/09.
8. Pui CH, Carroll WL, Meshinchi S, Arceci RJ. Biology, risk stratification, and therapy of pediatric acute leukemias: An update. J Clin Oncol. 2011;29(5):551-65. Epub 2011/01/12.
9. Wiemels J. Perspectives on the causes of childhood leukemia. Chem Biol Interact. 2012;196(3):59-67. Epub 2012/02/14.
10. Mullighan CG. Genomic analysis of acute leukemia. Int J Lab Hematol. 2009;31(4):384-97. Epub 2009/06/03.
11. Mullighan CG, Downing Jr. Genome-wide profiling of genetic alterations in acute lymphoblastic leukemia: Recent insights and future directions. Leukemia. 2009;23(7):1209-18. Epub 2009/02/27.
12. Zelent A, Greaves M, Enver T. Role of the TEL-AML1 fusion gene in the molecular pathogenesis of childhood acute lymphoblastic leukaemia. Oncogene. 2004;23(24):4275-83. Epub 2004/05/25.
13. Ford AM, Bennett CA, Price CM, Bruin MC, Van Wering ER, Greaves M. Fetal origins of the TEL-AML1 fusion gene in identical twins with leukemia. Proc Natl Acad Sci USA. 1998;95(8):4584-8. Epub 1998/05/16.
14. Pine SR, Wiemels JL, Jayabose S, Sandoval C. TEL-AML1 fusion precedes differentiation to pre-B cells in childhood acute lymphoblastic leukemia. Leuk Res. 2003;27(2):155-64. Epub 2003/01/16.
15. Greaves MF, Wiemels J. Origins of chromosome translocations in childhood leukaemia. Nat Rev Cancer. 2003;3(9):639-49. Epub 2003/09/03.
16. Arico M, Schrappe M, Hunger SP, Carroll WL, Conter V, Galimberti S, et al. Clinical outcome of children with newly diagnosed philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005. J Clin Oncol. 2010;28(31):4755-61. Epub 2010/09/30.
17. Teitell MA, PandolfiPP. Molecular genetics of acute lymphoblastic leukemia. Annu Rev Pathol-Mech. 2009;4:175-98. Epub 2008/09/12.
18. Clark SS, McLaughlin J, Crist WM, Champlin R, Witte ON. Unique forms of the abl tyrosine kinase distinguish Ph1-positive CML from Ph1-positive ALL. Science. 1987;235(4784):85-8. Epub 1987/01/02.
19. Ribeiro RC, Abromowitch M, Raimondi SC, Murphy SB, Behm F, Williams DL. Clinical and biologic hallmarks of the philadelphia chromosome in childhood acute lymphoblastic leukemia. Blood. 1987;70(4):948-53. Epub 1987/10/01.
20. Kharas MG, Fruman DA. ABL oncogenes and phosphoinositide 3-kinase: Mechanism of activation and downstream effectors. Cancer Res. 2005;65(6):2047-53. Epub 2005/03/23.
21. Salomoni P, Condorelli F, Sweeney SM, Calabretta B. Versatility of BCR/ABL-expressing leukemic cells in circumventing proapoptotic BAD effects. Blood. 2000;96(2):676-84. Epub 2000/07/11.
22. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348(11):994-1004. Epub 2003/03/15
23. Arico M, Valsecchi MG, Camitta B, Schrappe M, Chessells J, Baruchel A, et al. Outcome of treatment in children with philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med. 2000;342(14):998-1006. Epub 2000/04/06.
24. Armstrong SA, Staunton JE, Silverman LB, Pieters R, den Boer ML, Minden MD, et al. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet. 2002;30(1):41-7. Epub 2001/12/04.
25. Armstrong SA, Mabon ME, Silverman LB, Li A, Gribben JG, Fox EA, et al. FLT3 mutations in childhood acute lymphoblastic leukemia. Blood. 2004;103(9):3544-6. Epub 2003/12/13.
26. Brown KE, Guest SS, Smale ST, Hahm K, Merkenschlager M, Fisher AG. Association of transcriptionally silent genes with ikaros complexes at centromeric heterochromatin. Cell. 1997;91(6):845-54. Epub 1997/12/31.
27. Dovat S, Payne KJ. Tumor suppression in T cell leukemia - The role of ikaros. Leuk Res. 2010;34(4):416-7. Epub 2009/11/07.
28. Payne KJ, Dovat S. Ikaros and tumor suppression in acute lymphoblastic leukemia. Crit Rev Oncog. 2011;16(1-2):3-12. Epub 2011/12/14.
29. Dovat S, Song C, Payne KJ, Li Z. Ikaros, CK2 kinase, and the road to leukemia. Mol Cell Biochem. 2011;356(1-2):201-7. Epub 2011/07/14.
30. Song C, Li Z, Erbe AK, Savic A, Dovat S. Regulation of Ikaros function by casein kinase 2 and protein phosphatase 1. World J Biol Chem. 2011;2(6):126-31. Epub 2011/07/19.
31. Li Z, Song C, Ouyang H, Lai L, Payne KJ, Dovat S. Cell cycle-specific function of ikaros in human leukemia. Pediatr Blood Cancer. 2012;59(1):69-76.
32. Gurel Z, Ronni T, Ho S, Kuchar J, Payne KJ, Turk CW, et al. Recruitment of ikaros to pericentromeric heterochromatin is regulated by phosphorylation. J Biol Chem. 2008;283(13): 8291-300. Epub 2008/01/29.
33. Popescu M, Gurel Z, Ronni T, Song C, Hung KY, Payne KJ, et al. Ikaros stability and pericentromeric localization are regulated by protein phosphatase 1. J Biol Chem. 2009;284(20):13869-80. Epub 2009/03/14.
34. Mullighan CG, Miller CB, Radtke I, Phillips LA, Dalton J, Ma J, et al. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of ikaros. Nature. 2008;453(7191):110-4. Epub 2008/04/15.
35. Mullighan CG, Su X, Zhang J, Radtke I, Phillips LA, Miller CB, et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med. 2009;360(5):470-80. Epub 2009/01/09.
36. Tonnelle C, Dijon M, Moreau T, Garulli C, Bardin F, Chabannon C. Stage specific overexpression of the dominant negative ikaros 6 reveals distinct role of ikaros throughout human B-cell differentiation. Mol Immunol. 2009;46(8-9):1736-43. Epub 2009/03/17.
37. Waanders E, van der Velden VH, van der Schoot CE, van Leeuwen FN, van Reijmersdal SV, de Haas V, et al. Integrated use of minimal residual disease classification and IKZF1 alteration status accurately predicts 79% of relapses in pediatric acute lymphoblastic leukemia. Leukemia. 2011;25(2):254-8. Official Journal of the Leukemia Society of America, Leukemia Research Fund, UK. Epub 2010/11/26.
38. Den Boer ML, van Slegtenhorst M, De Menezes RX, Cheok MH, Buijs-Gladdines JG, Peters ST, et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: A genome-wide classification study. Lancet Oncol. 2009;10(2):125-34. Epub 2009/01/14.
39. Hunger SP, Raetz EA, Loh ML, Mullighan CG. Improving outcomes for high-risk ALL: Tr anslating new discoveries into clinical care. Pediatr Blood Cancer. 2011;56(6):984-93. Epub 2011/03/04.
40. Mullighan CG, Collins-Underwood JR, Phillips LA, Loudin MG, Liu W, Zhang J, et al. Rearrangement of CRLF2 in B-progenitor- And down syndrome-Associated acute lymphoblastic leukemia. Nat Genet. 2009;41(11):1243-6. Epub 2009/10/20.
41. Mullighan CG, Zhang J, Harvey RC, Collins-Underwood JR, Schulman BA, Phillips LA, et al. JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc Natl Acad Sci USA. 2009;106(23):9414-8. Epub 2009/05/28
42. Russell LJ, Capasso M, Vater I, Akasaka T, Bernard OA, Calasanz MJ, et al. Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia. Blood. 2009;114(13):2688-98. Epub 2009/07/31.
43. Mullighan CG, Goorha S, Radtke I, Miller CB, Coustan-Smith E, Dalton JD, et al. Genomewide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature. 2007;446(7137):758-64. Epub 2007/03/09.
44. Bousquet M, Broccardo C, Quelen C, Meggetto F, Kuhlein E, Delsol G, et al. A novel PAX5-ELN fusion protein identified in B-cell acute lymphoblastic leukemia acts as a dominant negative on wild-Type PAX5. Blood. 2007;109(8):3417-23. Epub 2006/12/21.
45. Cortes M, Wong E, Koipally J, Georgopoulos K. Control of lymphocyte development by the ikaros gene family. Curr Opin Immunol. 1999;11(2):167-71. Epub 1999/05/14.
46. Georgopoulos K. Haematopoietic cell-fate decisions, chromatin regulation and ikaros. Nat Rev Immunol. 2002;2(3):162-74. Epub 2002/03/27.
47. Aspland SE, Bendall HH, Murre C. The role of E2A-PBX1 in leukemogenesis. Oncogene. 2001;20(40):5708-17. Epub 2001/10/19.
48. Hunger SP, Li S, Fall MZ, Naumovski L, Cleary ML. The proto-oncogene HLF and the related basic leucine zipper protein TEF display highly similar DNA-binding and transcriptional regulatory properties. Blood. 1996;87(11):4607-17. Epub 1996/06/01.
49. Dear TN, Colledge WH, Carlton MB, Lavenir I, Larson T, Smith AJ, et al. The Hox11 gene is essential for cell survival during spleen development. Development. 1995;121(9):2909-15. Epub 1995/09/01.
50. Roberts CW, Shutter JR, Korsmeyer SJ. Hox11 controls the genesis of the spleen. Nature. 1994;368(6473):747-9. Epub 1994/04/21.
51. Hatano M, Roberts CW, Minden M, Crist WM, Korsmeyer SJ. Deregulation of a homeobox gene, HOX11, by the t(10;14) in T cell leukemia. Science. 1991;253(5015):79-82. Epub 1991/07/05.
52. Su XY, Della-Valle V, Andre-Schmutz I, Lemercier C, Radford-Weiss I, Ballerini P, et al. HOX11L2/TLX3 Is transcriptionally activated through T-cell regulatory elements downstream of BCL11B as a result of the t(5;14)(q35;q32). Blood. 2006;108(13):4198-201. Epub 2006/08/24.
53. Weng AP, Ferrando AA, Lee W, Morris JP, Silverman LB, Sanchez-Irizarry C, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science. 2004;306(5694):269-71. Epub 2004/10/09.
54. Palomero T, Lim WK, Odom DT, Sulis ML, Real PJ, Margolin A, et al. NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth. Proc Natl Acad Sci USA. 2006;103(48):18261-6. Epub 2006/11/23.
55. Milano J, McKay J, Dagenais C, Foster-Brown L, Pognan F, Gadient R, et al. Modulation of notch processing by gamma-secretase inhibitors causes intestinal goblet cell metaplasia and induction of genes known to specify gut secretory lineage differentiation. Toxicol Sci. 2004;82(1):341-58 An official Journal of the Society of Toxicology. Epub 2004/08/21.
56. Real PJ, Tosello V, Palomero T, Castillo M, Hernando E, de Stanchina E, et al. Gammasecretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia. Nat Med. 2009;15(1):50-8. Epub 2008/12/23.
57. Ciofani M, Zuniga-P fl ucker JC. Notch promotes survival of pre-T cells at the beta-selection checkpoint by regulating cellular metabolism. Nat Immunol. 2005;6(9):881-8. Epub 2005/08/02.
58. O'Neil J, Grim J, Strack P, Rao S, Tibbitts D, Winter C, et al. FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors. J Exp Med. 2007;204(8):1813-24. Epub 2007/07/25.
59. Thompson BJ, Buonamici S, Sulis ML, Palomero T, Vilimas T, Basso G, et al. The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia. J Exp Med. 2007;204(8):1825-35. Epub 2007/07/25.
60. Rubnitz JE, Pui CH. Recent advances in the treatment and understanding of childhood acute lymphoblastic leukaemia. Cancer Treat Rev. 2003;29(1):31-44. Epub 2003/03/14.